<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01415466</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1276001</org_study_id>
    <nct_id>NCT01415466</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Multiple-Dose, Cross-over Clinical Study to Investigate Pharmacokinetics and Drug-Drug Interaction Between Rosuvastatin and CS-866 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug
      interaction between rosuvastatin and CS-866 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods.((in case of CS-866, for 48 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods.(in case of CS-866, for 48 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCss,last</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods. (in case of CS-866, for 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss,inf</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods. (in case of CS-866, for 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,min</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods. (in case of CS-866, for 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Multiple blood samples will be collected for 72 hours after last dosing in each of the periods. (in case of CS-866, for 48 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of Rosuvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of CS-866 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R+O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cresto</intervention_name>
    <description>tablet, 20mg</description>
    <arm_group_label>R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmetec</intervention_name>
    <description>tablet, 40mg</description>
    <arm_group_label>O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cresto, Olmetec</intervention_name>
    <description>tablet, 20mg and 40mg</description>
    <arm_group_label>R+O</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male volunteers aged 20 to 50 years

          2. A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

        Exclusion Criteria:

          1. A subject who had any allergic history to any drug.

          2. A subject with sign or symptoms or previously diagnosed disease of liver, kidney,
             neurology, respiratory, endocrinology, hematology, cardiovascular, genitourinary,
             psychology, ophthalmic, dermatology and gastrointestinal function or other significant
             diseases

          3. History or suspicion of current drug abuse

          4. A subject who had received treatment with below listed drug within specified period
             prior to the first dose of study medication

               -  Within 1 month: drug known CYP inducer or inhibitor

               -  Within 2 weeks: Prescribed or herbal medicine

               -  Within 1 weeks: OTC medicine

               -  Within 2 days: Consumption of caffeine

          5. A subject who had participated in any other clinical study within the last 2 weeks

          6. A subject from whom over 400mL of blood was sampled(whole blood donation) within last
             2 weeks or plasma/platelet donation within 1 month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsoo Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>YONSEI UNIVERSITY HEALTH SYSTEM (YUHS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Health System (Yuhs)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

